A

Avience Biomedicals Ltd.

SME
ListedListed on 25 Jun 2026+90.0%

Price Range

₹196–208

Issue Size

₹ 22 Cr

Lot Size

1200 Shares

Min. Investment

₹ 2,35,200

Financial Summary

(in crores)
ParticularsFY 2024-25FY 2023-24
Operating Revenue4,523.62,396.4
Other Income73.1540.86
Total Income4,596.752,437.26
Total Expenses3,378.81,985.99
Profit Before Tax980.07295.86
Total Profit723.18215.16

Subscription Details

Subscription data not yet available

IPO Timeline

IPO Offer Start

18 Jun 2026

IPO Offer Ends

22 Jun 2026

Listing Date

25 Jun 2026

Use of Proceeds

#PurposeAmount (₹ Cr)
1Funding the working capital requirement of our Company82.5
2General Corporate Purposes39.721

Promoters

Deepa Choudhary

Promoter Shareholding

Pre-IPO

92.85%

Promoter stake

Post-IPO

64.59%

Promoter stake

Offered to Public

10,44,000

shares

Post Share Capital

35,42,885

shares

About the Company

Avience Biomedicals Limited is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) productsand medical devices in Noida, Uttar Pradesh, India. In vitro diagnostics (IVDs) are tests that can detect disease, conditions andinfections. In vitro simply means ‘in glass’, meaning these tests are typically conducted in test tubes and similar equipment, asopposed to in vivo tests, which are conducted in the body itself. In vitro tests can be done in laboratories, health care facilities oreven in the home. The tests themselves can be performed on a variety of instruments ranging from small, handheld tests to complexlaboratory instruments.Avience Biomedicals Limited commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM),Covid, Human Immunodeficiency Viruses (HIV), HBs AG, Malaria, Dengue and others aimed at aiding medical institutions withaffordable and good-quality solutions. Avience Biomedicals Limited has expanded its product range from IVD rapid test kits toinclude a comprehensive line of medical devices such as Serology products, Biochemistry Analyser and Biochemistry Reagents,showcasing a dedication to addressing various healthcare needs. Being purely into B2B and B2G market, our products cater toPathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing,the Company also act as distributors and traders of medical equipments

Use of Proceeds

1. Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh2. Funding the Working Capital Requirement of our Company3. To meet out the General Corporate Purposes